“…Furthermore, administration of exogenous CART inhibits glucagon secretion in human and rodent islets as well as in vivo in mice due to reduced alpha-cell exocytosis (Abels et al, 2016). Furthermore, exogenous CART protects beta-cells against glucotoxicity-induced cell death in vitro in INS-1 (832/13) beta-cells Abbreviations: alpha-KIC, alpha-ketoisocaproate; CART, cocaine-and amphetamine-regulated transcript; CARTPT, human gene encoding CART; FCCP, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; GSIS, glucose-stimulated insulin secretion; KD, knock-down; OM, oligomycin; RRP, ready releasable pool.and rat islets (Sathanoori et al, 2013). In addition, endogenous beta-cell CART is upregulated in T2D patients as well as in several rodent models of T2D (Abels et al, 2016;, likely as a homeostatic response attempting to overcome hyperglycemia.…”